BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8876871)

  • 1. Acute renal failure with amphotericin B in lipid emulsion.
    Gales MA; Gales BJ; Alford KM
    Ann Pharmacother; 1996 Sep; 30(9):1036. PubMed ID: 8876871
    [No Abstract]   [Full Text] [Related]  

  • 2. Amphotericin B in fat emulsion.
    Kintzel PE
    Am J Health Syst Pharm; 1996 Nov; 53(22):2701. PubMed ID: 8931810
    [No Abstract]   [Full Text] [Related]  

  • 3. Amphotericin B infused in 20% lipid emulsion.
    Ryan KA
    J Intraven Nurs; 1996; 19(3):123-5. PubMed ID: 8788829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia.
    Pascual B; Ayestaran A; Montoro JB; Oliveras J; Estibalez A; Julia A; Lopez A
    Ann Pharmacother; 1995 Dec; 29(12):1197-201. PubMed ID: 8672820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Use of amphotericin B in lipid emulsions: does it prevent its toxicity in critically ill patients?].
    Hernández G; Altermatt F; Bernucci F; Acuña D; Apablaza F; Valenzuela F; Lefio A; Pérez C; Bugedo G; Castillo L
    Rev Med Chil; 2000 Oct; 128(10):1101-7. PubMed ID: 11349508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case-control study of amphotericin B in a triglyceride fat emulsion versus conventional amphotericin B in patients with AIDS.
    Manfredi R; Chiodo F
    Pharmacotherapy; 1998; 18(5):1087-92. PubMed ID: 9758320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amphotericin B formulated in a lipid emulsion.
    Cleary JD
    Ann Pharmacother; 1996 Apr; 30(4):409-12. PubMed ID: 8729899
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study.
    Schöffski P; Freund M; Wunder R; Petersen D; Köhne CH; Hecker H; Schubert U; Ganser A
    BMJ; 1998 Aug; 317(7155):379-84. PubMed ID: 9694753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatal fat embolism following amphotericin B lipid complex injection.
    Tolentino LF; Tsai SF; Witt MD; French SW
    Exp Mol Pathol; 2004 Dec; 77(3):246-8. PubMed ID: 15507243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Amphotericin B-intralipid 20% combination. In vivo evaluation of its tolerability].
    Débat Zoguéreh D; Poignard P; Sorriaux A; Brouqui P
    Ann Med Interne (Paris); 1997; 148(1):100-2. PubMed ID: 9137701
    [No Abstract]   [Full Text] [Related]  

  • 11. [Amphotericin B. Lipid complex versus liposomes. Which, why, when?].
    Pahissa A
    Enferm Infecc Microbiol Clin; 1997 Jan; 15(1):1-3. PubMed ID: 9147499
    [No Abstract]   [Full Text] [Related]  

  • 12. Correlates of acute renal failure in patients receiving parenteral amphotericin B.
    Bates DW; Su L; Yu DT; Chertow GM; Seger DL; Gomes DR; Platt R
    Kidney Int; 2001 Oct; 60(4):1452-9. PubMed ID: 11576359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B.
    Barcia JP
    Pharmacotherapy; 1998; 18(4):874-6. PubMed ID: 9692667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amphotericin B toxicity reduced by administration in fat emulsion.
    Anderson RP; Clark DA
    Ann Pharmacother; 1995 May; 29(5):496-500. PubMed ID: 7655134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid formulations of amphotericin B.
    Jones E; Goldman M
    Cleve Clin J Med; 1998 Sep; 65(8):423-7. PubMed ID: 9769563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Best practice guidelines for the management of adverse events associated with amphotericin B lipid complex.
    Craddock C; Anson J; Chu P; Dodgson A; Duncan N; Gomez C; Mehta J; Sadullah S; Subudhi C; Yin JL
    Expert Opin Drug Saf; 2010 Jan; 9(1):139-47. PubMed ID: 19947901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amphotericin B--not so terrible.
    Bishara J; Weinberger M; Lin AY; Pitlik S
    Ann Pharmacother; 2001 Mar; 35(3):308-10. PubMed ID: 11261528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lipid derivatives of amphotericin B in treatment of systemic candidiasis].
    Rosenthal E
    Presse Med; 2000 Mar; 29(8):428. PubMed ID: 10738509
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk factors for nephrotoxicity associated with conventional amphotericin B therapy.
    Girmenia C; Cimino G; Micozzi A; Gentile G; Martino P
    Am J Med; 2002 Sep; 113(4):351. PubMed ID: 12361831
    [No Abstract]   [Full Text] [Related]  

  • 20. Amphotericin B and cardiac toxicity--a case report.
    el-Dawlatly AA; Gomaa S; Takrouri MS; Seraj MA
    Middle East J Anaesthesiol; 1999 Feb; 15(1):107-12. PubMed ID: 10068976
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.